Tumor Targeting and Immunotherapy Enabled By an Engineered Peptide-Fc Fusion

In this talk, I will discuss the discovery and development of a novel therapeutic approach to targeted cancer treatment, spanning a broad range of efforts in the areas of protein engineering, biochemical and biophysical analyses, and preclinical testing. This project has benefited significantly from multi-disciplinary expertise of scientists, engineers, and clinicians across several institutions, including Stanford, MIT, and Dana Farber; such highly collaborative science highlights a productive formula for addressing complex biomedical problems. In the spirit of the meeting theme of ‘translational medicine and bioengineering’, I will also discuss considerations for the successful development of protein biologics, including production yield, stability, therapeutic efficacy, toxicity, and immunogenicity.